2020
An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status
Ahluwalia M, Ali MA, Joshi RS, Park ES, Taha B, McCutcheon I, Chiang V, Hong A, Sinclair G, Bartek J, Chen CC. An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status. Neuro-Oncology Advances 2020, 3: vdaa152. PMID: 33506199, PMCID: PMC7810198, DOI: 10.1093/noajnl/vdaa152.Peer-Reviewed Original ResearchCumulative intracranial tumor volumeNumber of metastasesBRAF mutation statusMelanoma brain metastasesBrain metastasesStereotactic radiosurgeryMutation statusPrognostic scalesMelanoma patientsSurvival prognosticationIndependent cohortMultivariate Cox proportional hazards modelCox proportional hazards modelIntracranial tumor volumePrognostic assessment scaleMulti-institutional collaborationNet reclassification indexProportional hazards modelBM patientsMainstay therapyPatient characteristicsTumor characteristicsPrognostic importancePrognostic utilityReclassification index
2018
BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study
Mastorakos P, Xu Z, Yu J, Hess J, Qian J, Chatrath A, Taylor DG, Kondziolka D, Warnick R, Chiang V, Sheehan J. BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. Neurosurgery 2018, 84: 868-880. PMID: 29846702, PMCID: PMC6505443, DOI: 10.1093/neuros/nyy203.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesBrain metastasesBRAF inhibitorsStereotactic radiosurgeryBRAF mutationsIntracerebral hematomaDiagnosis of BMEffects of BRAFiMulticenter retrospective cohort studyIntracranial melanoma metastasesPD-1 inhibitorsMulticenter retrospective studyRetrospective cohort studyKaplan-Meier methodologyPositive prognostic factorBRAF V600 mutationBRAF mutation statusBRAF kinase inhibitorsMultivariate regression analysisWild-type BRAFCohort studyHazard ratioMedian survivalIndependent predictorsPrognostic factors